Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna's platform with plans to expand AB126, an unmodified exosome derived from proprietary neural stem cells, to other neurological indications including amyotrophic lateral sclerosis-…#gmp #boston #athens #arunabioinc #fda #ab126 #stevenstice #phd #cns #seansavitzmd
Source: Reuters: Health - Category: Consumer Health News Source Type: news